5 recruiting, 1 enrolling by invitation. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Hematologic Disease and Disorders: new trials by email Literature Review of Hematologic Disease and Disorders trials Research Report on Hematologic Disease and Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research Clonal Hematopoiesis, CCUS Clonal Cytopenia of Undetermined Significance | Recruiting | Clinical Hub for Interventional Research (CHOIR) | 100 | 2026-03-20 | 2026-05-13 | |
| Reconstruction Kinetics of γδ T Cells After Unrelated Cord Blood Transplantation Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders - Hematologic Disease and Disorders | Recruiting | Anhui Provincial Hospital | 100 | 2025-10-09 | 2026-08-24 | |
| A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma KLN-1010 - Multiple Myeloma in Relapse, Myeloma Multiple | Phase 1 | Recruiting | Kelonia Therapeutics, Inc. | 70 | 2025-07-16 | 2026-08-28 |
| Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide Tacrolimus, Cyclophosphamide, Mycofenolate mofetil - Hematologic Disease and Disorders, Hematopoietic Cell Transplant | Phase 2 | Recruiting | Northside Hospital, Inc. | 20 | 2025-07-03 | 2026-10-14 |
| Outcome of HSCT in Children at Ramathibodi Hospital Hematologic Disease and Disorders, Malignancies | Recruiting | Mahidol University | 200 | 2020-05-08 | 2026-10-05 | |
| Screening for Hematology Branch Protocols Hematologic Disease and Disorders, Donors | Enrolling by invitation | National Heart, Lung, and Blood Institute (NHLBI) | 10000 | 1996-12-31 | 2026-10-29 |
Disease (6) · Hematologic Diseases (6) · Neoplasms (2) · Anemia (1) · Blood Protein Disorders (1) · Cytopenia (1) · Genetic Diseases, Inborn (1) · Hematologic Neoplasms (1) · Hemostatic Disorders (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Neoplasms by Histologic Type (1) · Neutropenia (1)
Hemic and Lymphatic Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Agranulocytosis (1) · Blood Platelet Disorders (1) · Cardiovascular Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Hemorrhagic Disorders (1) · Leukocyte Disorders (1) · Leukopenia (1) · Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Plasma Cell (1)
Cyclophosphamide (1) · Tacrolimus (1)
Anhui Provincial Hospital (1) · Clinical Hub for Interventional Research (CHOIR) (1) · Kelonia Therapeutics, Inc. (1) · Mahidol University (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Northside Hospital, Inc. (1)
United States (3) · Australia (2) · China (1) · Thailand (1)
David J Young, M.D. (1) · Melhem Solh, MD (1) · Usanarat Anurathapan, MD (1)
PMID 23233586, PMID 23423745, PMID 27318038, PMID 29419434, PMID 29421292, PMID 29674506, PMID 29958797, PMID 30953027, PMID 32556286, PMID 32645444, PMID 33734005, PMID 34262142, PMID 38281591, PMID 7742535, PMID 8877390